A New Animal Model of Insulin-Glucose Dynamics in the Intraperitoneal Space Enhances Closed-Loop Control Performance.
暂无分享,去创建一个
Don Cohen | Eyal Dassau | Francis J. Doyle | Howard Zisser | Ankush Chakrabarty | Howard C. Zisser | Peter C. Lord | Alan D. Cherrington | Ben Farmer | Justin M. Gregory | L. Merkle Moore | Philip E. Williams | Brian Michael Shelton | F. Doyle | E. Dassau | H. Zisser | A. Cherrington | J. Gregory | Ben Farmer | A. Chakrabarty | P. Williams | Don Cohen | L. M. Moore | Brian Michael Shelton | B. Shelton | Eyal Dassau
[1] G. Steil,et al. Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era , 2015, Diabetes Care.
[2] E. Renard,et al. Implantable insulin pumps: an effective option with restricted dissemination. , 2014, The lancet. Diabetes & endocrinology.
[3] R. E. Carlson,et al. Monotone Piecewise Cubic Interpolation , 1980 .
[4] Eric Renard,et al. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. , 2010, Diabetes technology & therapeutics.
[5] C. Cobelli,et al. In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.
[6] Eric Renard,et al. A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. , 2011, Diabetes Technology & Therapeutics.
[7] Hui-yu Liu,et al. Insulin Is a Stronger Inducer of Insulin Resistance than Hyperglycemia in Mice with Type 1 Diabetes Mellitus (T1DM)* , 2009, The Journal of Biological Chemistry.
[8] D. Edgerton,et al. Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes , 2015, Diabetes.
[9] Lauren M. Huyett,et al. Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms , 2014, Diabetes Care.
[10] S. Colberg,et al. Pumping Insulin During Exercise , 2002, The Physician and sportsmedicine.
[11] W. Blackard,et al. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. , 1975, The Journal of clinical investigation.
[12] S. Yen,et al. Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. , 1974, The New England journal of medicine.
[13] Eyal Dassau,et al. Event-Triggered Model Predictive Control for Embedded Artificial Pancreas Systems , 2018, IEEE Transactions on Biomedical Engineering.
[14] Ahmad Haidar,et al. The Artificial Pancreas: How Closed-Loop Control Is Revolutionizing Diabetes , 2016, IEEE Control Systems.
[15] M. Matsuda,et al. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man , 1994, Diabetologia.
[16] L. Kvols,et al. Distribution of somatostatin receptors in normal and tumor tissue. , 1990, Metabolism: clinical and experimental.
[17] Timothy J. Garrett,et al. Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes , 2017, Scientific Reports.
[18] G. Steil,et al. Evaluation of the Effect of Gain on the Meal Response of an Automated Closed-Loop Insulin Delivery System , 2006, Diabetes.
[19] R. Gans,et al. Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia , 2014, Clinical endocrinology.
[20] Cesar C. Palerm,et al. Physiologic insulin delivery with insulin feedback: A control systems perspective , 2011, Comput. Methods Programs Biomed..
[21] E. Renard,et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion , 2009, Diabetes, obesity & metabolism.
[22] A BuckinghamBruce,et al. Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp. , 2016 .
[23] H Gin,et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. , 2003, Diabetes & metabolism.
[24] Garry M. Steil,et al. Automated insulin delivery for type 1 diabetes , 2006 .
[25] C. J. Goodner,et al. Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas , 1974, Science.
[26] C Jaffiol,et al. Insulin Underdelivery From Implanted Pumps Using Peritoneal Route: Determinant role of insulin pump compatibility , 1996, Diabetes Care.
[27] Complications of the Pump Pocket May Represent a Significant Cause of Incidents With Implanted Systems for Intraperitoneal Insulin Delivery , 1994, Diabetes Care.
[28] Stuart A Weinzimer,et al. Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study , 2012, Journal of diabetes science and technology.
[29] Dale E. Seborg,et al. Control-Relevant Models for Glucose Control Using A Priori Patient Characteristics , 2012, IEEE Transactions on Biomedical Engineering.
[30] A. Cherrington,et al. Intraportal glucose delivery enhances the effects of hepatic glucose load on net hepatic glucose uptake in vivo. , 1991, The Journal of clinical investigation.
[31] Eyal Dassau,et al. Design and in silico evaluation of an intraperitoneal-subcutaneous (IP-SC) artificial pancreas , 2014, Comput. Chem. Eng..
[32] R. Hovorka. Continuous glucose monitoring and closed‐loop systems , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[33] G. Skjåk‐Braek,et al. SUCCESSFUL REVERSAL OF SPONTANEOUS DIABETES IN DOGS BY INTRAPERITONEAL MICROENCAPSULATED ISLETS , 1992, Transplantation.
[34] E Renard,et al. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. , 2006, Diabetes & metabolism.
[35] L. Laffel,et al. Impact of Carbohydrate Counting on Glycemic Control in Children With Type 1 Diabetes , 2009, Diabetes Care.
[36] C Cobelli,et al. Compartmental modeling of glucagon kinetics in the conscious dog. , 1995, Metabolism: clinical and experimental.
[37] M. Morari,et al. Internal model control: PID controller design , 1986 .
[38] A. Cherrington,et al. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.
[39] Eyal Dassau,et al. Design and Evaluation of a Robust PID Controller for a Fully Implantable Artificial Pancreas , 2015, Industrial & engineering chemistry research.
[40] Thomas F. Edgar,et al. Process Dynamics and Control , 1989 .
[41] R. Gans,et al. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes. , 2016, The Journal of clinical endocrinology and metabolism.
[42] R. Gans,et al. Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability. , 2015, Diabetes technology & therapeutics.
[43] J Hans DeVries,et al. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. , 2014, Diabetes technology & therapeutics.
[44] G. Steil,et al. Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.
[45] Jennings,et al. The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. , 1976, The Journal of clinical investigation.
[46] D. Cuthbertson,et al. Obesity-related metabolic dysfunction in dogs: a comparison with human metabolic syndrome , 2012, BMC Veterinary Research.
[47] D. Goldstein,et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. , 2002, Diabetes care.
[48] G. Pozza,et al. Intraperitoneal Insulin Absorption After Lona-Term Intraperitoneal Insulin Therapy , 1995, Diabetes Care.
[49] Eyal Dassau,et al. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control‐based fully‐automated artificial pancreas in patients with type 1 diabetes: a pilot study , 2017, Diabetes, obesity & metabolism.
[50] Eyal Dassau,et al. Embedded Control in Wearable Medical Devices: Application to the Artificial Pancreas , 2016 .
[51] C. C. Palerm,et al. Closed-Loop Insulin Delivery Using a Subcutaneous Glucose Sensor and Intraperitoneal Insulin Delivery , 2009, Diabetes Care.
[52] Lauren M. Huyett,et al. Glucose Sensing in the Peritoneal Space Offers Faster Kinetics Than Sensing in the Subcutaneous Space , 2014, Diabetes.
[53] M. Hanefeld,et al. Postprandial glucose regulation and diabetic complications. , 2004, Archives of internal medicine.
[54] A. Fougner,et al. Intraperitoneal Glucose Sensing is Sometimes Surprisingly Rapid , 2016 .
[55] E. Araki,et al. Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas , 2003, Journal of Artificial Organs.
[56] R. Eaton,et al. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. , 1983, The Journal of clinical endocrinology and metabolism.